Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study

References

• National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Review (CSR) 1975-2017. https://seer.cancer.gov/csr/1975_2017/. Accessed March 28, 2023.
   Google Scholar
• National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia–Acute Myeloid Leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html. Accessed March 28, 2023.
   Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Cui L, Liu Y, Pang Y, et al. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Ther. 2020;27(1–2):1–14. doi:10.1038/s41417-019-0119-5
   PubMed Web of Science ®Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra1406184
   PubMed Web of Science ®Google Scholar
• Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16(9):1025–1036. doi:10.1016/S1470-2045(15)00201-6
   PubMed Web of Science ®Google Scholar
• Khaldoyanidi S, Nagorsen D, Stein A, et al. Immune biology of acute myeloid leukemia: implications for immunotherapy. J Clin Oncol. 2021;39(5):419–432. doi:10.1200/JCO.20.00475
   PubMed Web of Science ®Google Scholar
• Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126(14):3192–3201. doi:10.1002/cncr.32909
   PubMed Web of Science ®Google Scholar
• Jen EY, Xu Q, Schetter A, et al. FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res. 2019;25(2):473–477. doi:10.1158/1078-0432.CCR-18-2337
   PubMed Web of Science ®Google Scholar
• Allen C, Zeidan AM, Bewersdorf JP. BiTEs, DARTS, BiKEs and TriKEs-are antibody based therapies changing the future treatment of AML? Life. 2021;11(6):465. doi:10.3390/life11060465
   PubMedGoogle Scholar
• Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123(3):356–365. doi:10.1182/blood-2013-08-523548
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–1516. doi:10.1016/S0140-6736(12)60485-1
   PubMed Web of Science ®Google Scholar
• Jen EY, Ko CW, Lee JE, et al. FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24(14):3242–3246. doi:10.1158/1078-0432.CCR-17-3179
   PubMed Web of Science ®Google Scholar
• Marofi F, Rahman HS, Al-Obaidi ZMJ, et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Res Ther. 2021;12(1):465. doi:10.1186/s13287-021-02420-8
   PubMed Web of Science ®Google Scholar
• Hofmann S, Schubert ML, Wang L, et al. Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML). J Clin Med. 2019;8(2):200. doi:10.3390/jcm8020200
   PubMed Web of Science ®Google Scholar
• Friedrich M, Henn A, Raum T, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13(6):1549–1557. doi:10.1158/1535-7163.MCT-13-0956
   PubMed Web of Science ®Google Scholar
• Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2013;27(5):1107–1115. doi:10.1038/leu.2012.341
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554–561. doi:10.1182/blood-2013-09-527044
   PubMed Web of Science ®Google Scholar
• Harrington KH, Gudgeon CJ, Laszlo GS, et al. The broad anti-AML activity of the CD33/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk. PLOS One. 2015;10(8):e0135945. doi:10.1371/journal.pone.0135945
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi:10.1182/blood-2014-05-552729
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649. doi:10.1200/JCO.2003.04.036
   PubMed Web of Science ®Google Scholar
• Liu J, Tong J, Yang H. Targeting CD33 for acute myeloid leukemia therapy. BMC Cancer. 2022;22(1):24. doi:10.1186/s12885-12021-09116-12885
   PubMed Web of Science ®Google Scholar
• Zhou S, Liu M, Ren F, et al. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9(1):38. doi:10.1186/s40364-021-00294-9
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943–947. doi:10.1634/theoncologist.2018-0028
   PubMed Web of Science ®Google Scholar
• Khadka RH, Sakemura R, Kenderian SS, et al. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 2019;11(10):851–857. doi:10.2217/imt-2019-0074
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Walter R, Subklewe M, et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). J Clin Oncol. 2020;38(Suppl_15):7508–7508. doi: 10.1200/JCO.2020.38.15_suppl.7508
   Google Scholar
• Lewis JH, Khaldoyanidi SK, Britten CD, et al. Clinical significance of transient asymptomatic elevations in aminotransferase (TAEAT) in oncology. Am J Clin Oncol. 2022;45(8):352–365. doi:10.1097/COC.0000000000000932
   PubMed Web of Science ®Google Scholar
• Knorr DA, Goldberg AD, Stein EM, et al. Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. Leuk Lymphoma. 2019;60(14):3350–3362. doi:10.1080/10428194.2019.1639167
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar